A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the clinical safety and tolerability and
to assess the efficacy of 100 mg, 200 mg, and 300 mg BID dextofisopam compared with placebo
in female outpatients with diarrhea-predominant or alternating irritable bowel syndrome
(IBS).